Stockreport

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

iTeos Therapeutics, Inc.  (ITOS) 
PDF - Multiple TIGIT clinical data readouts anticipated throughout 2025, including 400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab [Read more]